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This study explored the potential utility of gait analysis using a single sensor unit (inertial measurement unit [IMU]) as a simple 
tool to detect peripheral neuropathy in people with diabetes. Seventeen people (14 men) aged 63±9 years (mean±SD) with dia-
betic peripheral neuropathy performed a 10-m walk test instrumented with an IMU on the lower back. Compared to a reference 
healthy control data set (matched by gender, age, and body mass index) both spatiotemporal and gait control variables were dif-
ferent between groups, with walking speed, step time, and SDa (gait control parameter) demonstrating good discriminatory pow-
er (receiver operating characteristic area under the curve >0.8). These results provide a proof of principle of this relatively simple 
approach which, when applied in clinical practice, can detect a signal from those with known diabetes peripheral neuropathy. The 
technology has the potential to be used both routinely in the clinic and for tele-health applications. Further research should focus 
on investigating its efficacy as an early indicator of or effectiveness of the management of peripheral neuropathy. This could sup-
port the development of interventions to prevent complications such as foot ulceration or Charcot’s foot. 
Keywords: Accelerometry; Diabetes complications; Diabetic neuropathies; Gait
Corresponding author: Johnny Collett   https://orcid.org/0000-0003-4138-2589  
Movement Science Group, Oxford Brookes University, Oxford, OX3 0BP, UK 
E-mail: jcollett@brookes.ac.uk
Received: Apr. 29, 2017; Accepted: Oct. 16, 2017
INTRODUCTION
Diabetic peripheral neuropathy (DPN) affects over 50% of 
people with diabetes mellitus [1]. DPN can lead to reduced in-
dependence, lower rates of perceived health and higher mortal-
ity rates [1,2] as well as a range of complications including neu-
ropathic ulceration, Charcot’s feet, and eventual lower limb 
amputation. DPN itself often begins years before a formal diag-
nosis is made [2]. Timely identification of DPN enables the in-
troduction of preventative management, education, and advice 
measures, which can reduce the rate of the complications of 
DPN. However, many individuals are not diagnosed with DPN 
promptly, and hence fail to receive timely intervention [3].
The effect DPN has on gait is highlighted in recent systematic 
reviews [4,5]. However, whilst the reviews demonstrate tem-
poral-spatial gait parameters are significantly affected by DPN 
[4], gait analysis does not have sufficiently utility to be used 
routinely in primary clinical settings. This may be partly due to 
most objective gait analysis reliant on technology such as pres-
sure mats, specialised treadmills, or laboratories with optical 
motion capture and force measurement, being time, space and 
resource intensive and thus a barrier to routine practice [6]. 
Inertial measurement units (IMUs) are relatively cheap, robust, 
and easy to use, and also contained within smart phones, 
opening the possibility for a telehealth application [7]. The data 
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gait parameters and provide sensitive data indicative of gait 
deficits found in various neurological pathologies [7-10]. 
However, these methodologies have yet to be explored in a pri-
marily DPN pathology. 
We propose that gait screening may have the potential to aid 
in the detection and monitoring of DPN, supporting interven-
tions to prevent complications associated with the diabetic 
foot, which could increase mobility function and quality of life 
as indicated by results in other neurological conditions [11,12]. 
Due to the novelty of the proposed gait assessment mytholo-
gies in this area, we set out to test the principle that single, torso-
mounted, IMU gait analysis can differentiate those with DPN 




People were recruited from the Oxford Centre for Diabetes, 
Endocrinology & Metabolism (OCDEM) at the Oxford Uni-
versity Hospitals NHS Foundation Trust (Oxford, UK). Inclu-
sion criteria were (1) a clinical diagnosis of DPN (diagnosed 
on the basis of clinical history and physical examination in-
cluding tests of light touch and vibration sensation in line with 
international guidelines [13]); (2) failure of the monofilament 
test (10 and 75 g); and (3) a score of ≥8 on the Rivermead mo-
bility index and able to walk independently with or without 
walking aid. Exclusion criteria were (1) a history of amputation 
or active ulcers (those with previously healed ulcers were eligi-
ble); (2) insufficient capacity to consent or uncontrolled psy-
chiatric symptoms; (3) confounding gait factors such as neuro-
logical conditions, knee replacements, amputations, or pad-
ding; and (4) pregnancy. The study was conducted according 
to the Declaration of Helsinki and received National Research 
Ethics Committee approval (NRES: 11/SC/0218).
Reference control data were extracted from a database held 
by Oxford Brookes University (BIG Database, Oxford, UK). 
The database consists of data from 2,030 individuals aged be-
tween 5 and 80 years with no known pathology affecting gait 
primarily obtained from visitors to the Science Museum Lon-
don from April to July 2012 (UREC: 100490). The data base 
can be interrogated to provide reference data according to de-
sired demographic. Healthy ageing gait performance has been 
well described in the literature generally resulting in slower 
gait [14] and reduced gait symmetry [15], with similar results 
also reported for those with higher subcutaneous thigh fat [16] 
as well as for DPN [4]. Therefore, based on available demo-
graphic data age (REFAGE) and BMI (REFBMI) reference data 
was extracted from the database, whereby all individuals with-
in 1 standard deviation of age and BMI of the DPN group were 
included.
Assessment
After obtaining informed consent, demographic data of gen-
der, age, height, weight, shoe size, leg length, time since diabe-
tes diagnosis, Rivermead mobility index, and Barthel index 
were obtained. 
Gait analysis for both groups was performed during a stan-
dard 10-m test by attaching an IMU to the lower back that 
sampled triaxial accelerometer and gyroscope data at a fre-
quency of 100 Hz. Assessment for those with DPN took place 
at OCDEM in a corridor free from obstacles. Further method-
ology on how gait parameters were derived has been previous-
ly extensively described [8-10,17,18]. 
Spatiotemporal parameters derived were step time (ms), ca-
dence (steps/min), stride length (m), and walking speed (m/s).
Gait control parameters calculated were beta (deg), SDa 
(au), SDb (au), ratio (au) [10], and walk ratio (mm/[steps/
min]) which have been described as indicators of neuro motor 
control [19]. 
Statistical analysis 
Group differences were assessed by means of independent 
samples t-test or chi-square statistic. Discriminatory power 
was further investigated using receiver operating characteristic 
(ROC) curves, by means of the area under the curve (AUC). 
Statistical analysis was performed using, compare means, cross 
tabs, and ROC curve procedures in SPSS version 22 (IBM Co., 
Armonk, NY, USA). 
RESULTS
Descriptive data
Seventeen people (14 men) with DPN and 42 (30 men) con-
trols were included in analysis 63.2±9.2 years (mean±SD). 
There was no difference in age, gender ratio, height, or BMI 
between groups (P>0.05) (Table 1). DPN was confirmed by 
none of the participants responding to the 75 or 10 g monofila-
ment test performed by a specialist diabetes podiatrist [20]. 
Baseline glycosylated hemoglobin was 8.8%±1.0% (73.3±11.5 
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mmol/mol) and all patients had evidence of microvascular dis-
ease (pre-proliferative retinopathy or urinary microalbumin-
uria). The majority (eight people) scored 14 on the RMI which 
indicated little impairment to functional mobility, but not able 
to run or walk fast without a limp.
Gait analysis
Comparison between DPN and control groups can be found 
in Table 2, differences were found for all spatiotemporal and 
control variables except for stride length (P<0.05). Walking 
speed produced the greatest discriminatory power (AUC= 
0.975), with good discriminatory power (AUC >0.8) also 
found for step time and SDa and fair discriminatory power 
(AUC >0.7) found for cadence, beta, and ratio.
DISCUSSION
This proof of principle study found, for the first time that a sin-
gle IMU used in the clinical setting during a 10-m walk has the 
potential to discriminate those with DPN compared to healthy 
walking.
We intentionally selected those with established DPN in or-
der to determine if we could detect the spatiotemporal gait 
deficits previously described in this population and found our 
Table 1. Descriptive data
Demographic DPN (n=17) Control (n=42) Deltaa (P value)
Age, yr 63±9 (46–81) 61±4 (54–72) 2±2 (0.307)
Sex, male:female 14:3 30:12 X2 (0.883)
Height, m 1.78±0.9 (1.56–1.91) 1.77±0.9 (1.49–1.93) 0±0 (0.882)
BMI, kg/m2 33.6±7.6 (24.1–51.7) 31.6±3.9 (25.1–44.6) 2.0±1.9 (0.320)
Time since diagnosis diabetes 24±13 (3–49) - -
Barthel index 19±1 (15–20) - -
RMI 13±2 (9–15) - -
Values are presented as mean±standard deviation (range). 
DPN, diabetic peripheral neuropathy; BMI, body mass index; RMI, rivermead mobility index. 
aDelta (between group difference; DPN–Control) reported with P value of independent samples t-test or for nominal data P value for chi-sqaure 
statistic reported.
Table 2. Gait assessment data
Gait parameter DPN Control P valuea ROC-AUC (95%CI) ROC P valueb
Spatiotemporal 
   Step time, msec 650±117 543±47 0.002 0.804 (0.657–0.950) >0.001
   Stride length, m 1.33±0.16 1.41±0.17 0.066 0.632 (0.466–0.799) 0.114
   Cadence, steps/min 95±16 112±10 0.001 0.797 (0.650–0.944) >0.001
   Walking speed, m/sec 0.85±0.23 1.34±0.18 >0.001 0.975 (0.943–1.000) >0.001
Control
   Beta 27±10 34±10 0.014 0.735 (0.600–0.870) 0.005
   SDa 1.98±0.36 3.91±1.99 >0.001 0.849 (0.748–0.950) >0.001
   SDb 0.56±0.14 0.91±0.56 >0.001 0.667 (0.533–0.800) 0.046
   Ratio 3.67±0.94 4.86±2.30 0.044 0.782 (0.649–0.914) 0.001
   Walk ratio 7.2±1.1 6.4±1.0 0.012 0.696 (0.551–0.841) 0.019
Values are presented as mean±standard deviation.
DPN, diabetic peripheral neuropathy; ROC-AUC, receiver operating characteristic area under the curve; CI, confidence interval.
aIndependent samples t-test probability value, coefficient reported, with 95% confidence intervals, bReceiver operating characteristic probability 
value.
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results were similar to those reported in recent reviews [4,5]. 
Interestingly, in our DPN cohort, with minimal functional 
mobility deficits, walking speed was the most sensitive param-
eter and average walking speeds in the DPN group was just 
above the 0.8 m/sec cut-off indicative of frailty in the elderly 
[21]. Furthermore, this reduction in walking speed can be pri-
marily attributed to temporal rather than spatial changes, as no 
significant difference were found in stride length compared to 
control. A previous study, also using a single lower back 
mounted IMU to measure gait, in those with diabetes but ex-
cluding those with DPN, found the reduction in walking speed 
compared to control was primarily due to spatial gait changes, 
as they found no significant difference in cadence but a signifi-
cantly reduced stride length [22]. Whilst, we cannot generalise 
from this proof of principle study these results are consistent 
with the results of a recent meta-analysis that gait deficits differ 
between people with diabetes with and without DPN [5].
Non-linear gait measures may offer further insight into gait 
dynamics in diabetes than revealed by traditional spatial tem-
poral measurement. Khalaf et al. [23] derived gait entropy 
from the plantar pressure wave forms during stance and found 
an entropy was difference between those with DPN and those 
with diabetes without complication. In the current study we 
employed a non-linear approached that utilizes the dynamic 
similarity of the periodic wave forms produced by the centre of 
mass during walking, that can easily and rapidly be obtained 
through placing an IMU on the lower back of the participant. 
Whilst, this is the first time this methodology has been applied 
in DPN, it has have been previously shown utility in neurologi-
cal populations in determination of gait control parameters 
that have shown to be sensitive to subtle gait disturbances in 
movement disorders [8,9]. The ‘ratio’ parameter has been 
found to differentiate those with the Huntington’s gene but not 
displaying symptoms from healthy control walking [9] and in 
Parkinson’s disease SDa was found to account for differences 
with healthy walking [10]. In the current study, we found SDa 
had good discriminatory power, with beta and ratio parame-
ters having ‘fair’ discriminatory power. These the results are 
encouraging that DPN may present with a characteristic signa-
ture and warrant further investigation in those with less severe 
or pre-symptomatic DPN. In addition these gait measures in 
combination with assessments of the severity of the neuropathy 
such as monfiliment, vibration pressure threshold, and bioth-
ersiometer techniques may improve our understanding of the 
functional effects of the pathology and support more efficient 
diagnosis and monitoring.
Our results demonstrate that a relatively cheap, easy to use 
single sensor approach can differentiate those with severe DPN 
over a short-distance walking test when compared to age and 
BMI matched reference data. Indeed whilst, the potential ben-
efits of large scale gait analysis ‘in the field’ and reference data-
bases have been proposed, to date no suitable methodology 
has been established [24]. A simple methodology, such as the 
one presented, might assist with identification of those at risk 
and facilitate earlier diagnosis DPN resulting in a more effi-
cient management. Future studies are therefore indicated and 
should focus more on people at risk off or with mild DPN. 
Longitudinal studies may provide insights into interindividual 
changes and define parameters which identify when a person 
with diabetes has clinically relevant neuropathy and the utility 
of the technology for clinicians ‘in the field’ and for telehealth 
applications.
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